Gridai Technologies's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gridai Technologies (GRDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gridai Technologies vs Its Competitors
- Scale: Gridai Technologies ranks #356 of 549 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Gridai Technologies accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GRDX Sales vs. its Competitors, Q2 2026
Gridai Technologies generated 100.00 % of the combined sales of its peer group.
Gridai Technologies's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gridai Technologies Corp | - | - | - | Yes |
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GRDX Stock Performance relative to its Competitors
GRDX Stock Performance relative to High-Confidence Competitors
GRDX Stock Performance relative to Similar-Size Competitors
Gridai Technologies's Competitors Named by the Company
Competitive relationships identified from Gridai Technologies reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| VIVUS, Inc. | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Allergan plc. | Company report | 85% |
| Chiesi Farmaceutici S.p.A. | Company report | 85% |
| Nestlé S.A. | Company report | 85% |
| Merck & Co. Inc. | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| BioNTech SE | Company report | 85% |
| Moderna, Inc. | Company report | 85% |
| Ridgeback Biotherapeutics | Company report | 85% |
| AstraZeneca plc. | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Asymchem Inc. | Company report | 85% |
| ANA Therapeutics | Company report | 85% |
| NeuroBo Pharmaceuticals, Inc. | Company report | 85% |
| Neu | Company report | 85% |
Company report basis, confidence, active dates and source counts for Gridai Technologies's named competitors require a Commercial License.
Methodology: relationships are extracted from Gridai Technologies reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.